Kymera Strikes License Agreement Deals With Sanofi, Gilead
Sanofi, Gilead sign License Agreement with Kymera for protein degrader programs.
Read More
Category: Dealstreet
Vor Bio and RemeGen Seal $4B Global License Agreement
Vor Bio, RemeGen sign Global License Agreement for RC98 development.
Read More
Novartis Inks $750M Flagship Pact for Cardio Innovation
Novartis makes a $750M flagship pact to address cardiovascular disease innovation.
Read More
Gilead Taps Kymera in $750M Oncology Deal to Harness Molecular Glue Degraders
Gilead and Kymera seal a $750M deal for innovative CDK2 molecular glue degraders in oncology.
Read More
SINTX Enters the $1.3B Foot and Ankle Implants Market with SiNAPTIC Acquisition
SINTX acquires SiNAPTIC assets, targeting the $1.3B foot and ankle fusion implant market.
Read More